Table 1 Clinical characteristics, MGMT promoter methylation and FISH analysis of eight primary GBMs.
GBM sample | Sex | Age years | [M1]Number CD133 (%) | Stage | Tumour | Tumour Location | Resection | DFP months | Survival Days[M2] | Radiotherapy | Chemotherapy | Response | MGMT Methylation | EFGR (% cells) | PTEN (% cells) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
G2 | M | 73 | 2300 (0'5%) | Death | GBM | Temporal | Total | 9 | 398 | Cranial+Boost | TMZ | CR | No met | Amplification (74%) | del (46%) |
G4 | M | 70 | 37000 (3'2%) | Death | GBM | Temporal | Total | 5 | 479 | Cranial | - | NR | Met | Polysomy (61%) | del (86%) |
G5 | F | 68 | 6000 (1'5%) | Alive | GBM | Frontal | subtotal | 8 | 630 | Cranial+Boost | TMZ | PR | Met | Polysomy (55%) | del (64%) |
G6 | M | 65 | 6000 (1'6%) | Death | GBM | Multifoci | subtotal | 5,5 | 410 | Cranial | - | CR | No Met | Polysomy (47%) | Normal |
G7 | M | 59 | 4800 (0'6%) | Death | GBM | Frontal | Total | 3 | 192 | Cranial | TMZ | P | No met | Amplification (54%) | del (40%) |
G8 | M | 65 | 6000 (0'7%) | Alive | GBM | Temporal | Total | 4,5 | 166 | Cranial | TMZ | P | Met | Normal | del(70%) |
G9 | M | 69 | 2900 (0'1%) | Death | GBM | Parietal | subtotal | 2 | 108 | Cranial+Boost | - | P | nd | Normal | Normal |
G11 | F | 76 | 13000 (1'7%) | Death | GBM | Tempo-parietal | Total | 6 | 377 | Cranial+Boost | TMZ | NR | No met | Amplification (72%) | del (79%) |